Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova

admin by admin
November 14, 2024
in Stock
0
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

By Leroy Leo

(Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a similar therapy from Summit Therapeutics (NASDAQ:SMMT) outperformed its blockbuster Keytruda in a late-stage trial in the country.

The deal allows Merck (NS:PROR) to take over development of privately held LaNova Medicines’ LM-299, the companies said on Thursday.

The drug candidate targets a protein called PD-1, which prevents the immune system from killing cancerous cells. It also curbs levels of another protein called VEGF, which can encourage tumor growth if found in excess.

Under the agreement, Merck will pay $588 million upfront. LaNova is also eligible to receive up to $2.7 billion in milestone payments.

In September, Summit and its partner Akeso released data that showed patients using their drug ivonescimab, which targets the same proteins, had significantly better survival rates than those on Keytruda.

This class of drug has been attracting increased interest for deals. On Wednesday, German drugmaker BioNTech (NASDAQ:BNTX) said it would acquire China’s Biotheus to gain access to its so-called bi-specific antibody that targets PD-1 and VEGF.

BMO analyst Evan Seigerman said the LaNova deal offers a hedge to Merck after the data shown by Summit and others.

“The company (Merck) still maintains the best-in-class PD-1 (in Keytruda) with a wall of clinical data and a rapidly advancing pipeline of other modalities to back it,” Seigerman added. “LaNova’s LM-299 simply adds another arrow to Merck’s arsenal.”

Keytruda became the world’s biggest-selling drug last year, with sales of about $25 billion. But the therapy is set to lose its patent protection by the end of the decade, pushing Merck to scout for deals.

This post appeared first on investing.com

Previous Post

General Mills to acquire Whitebridge Pet Brands for $1.45 billion

Next Post

Australian supermarket giants face class action over ‘dodgy’ discounts

admin

admin

Next Post
Australian supermarket giants face class action over ‘dodgy’ discounts

Australian supermarket giants face class action over ‘dodgy’ discounts

Trending News

Movement Labs eyes $100 million in fresh capital, $3 billion valuation

Movement Labs eyes $100 million in fresh capital, $3 billion valuation

January 8, 2025
Can Boeing’s enhanced safety measures stabilize its stock price in 2025?

Can Boeing’s enhanced safety measures stabilize its stock price in 2025?

January 3, 2025
Revolut tops $1 billion in profit as crypto trading, growing user base fuel growth

Revolut tops $1 billion in profit as crypto trading, growing user base fuel growth

April 24, 2025
Subscribe to Insightful Word


    Recent News

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    August 7, 2025
    Affirm stock price is rising: is it a buy before earnings?

    Affirm stock price is rising: is it a buy before earnings?

    August 7, 2025
    Intel stock plunges sharply after Trump calls on CEO to resign: here’s why rebound may take time

    Intel stock plunges sharply after Trump calls on CEO to resign: here’s why rebound may take time

    August 7, 2025
    Goldman Sachs boosts Nvidia price target to $200 ahead of Q2 earnings

    Goldman Sachs boosts Nvidia price target to $200 ahead of Q2 earnings

    August 7, 2025

    Recent News

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    August 7, 2025
    Affirm stock price is rising: is it a buy before earnings?

    Affirm stock price is rising: is it a buy before earnings?

    August 7, 2025

    Latest News

    • Dow futures soar 250 points today: 5 things to know before Wall Street opens
    • Affirm stock price is rising: is it a buy before earnings?
    • Intel stock plunges sharply after Trump calls on CEO to resign: here’s why rebound may take time

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.